Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04005690 | Targeted Pathway Inhibition in Patients With Pancreatic Cancer | EARLY_PHASE1 | RECRUITING | 90 | — | — | Aug 1, 2019 | Feb 1, 2028 | Feb 27, 2026 | 1 | United States |
Will be estimated with a 95% confidence interval (CI).
| Arm | Type | Description |
|---|---|---|
| Arm Olaparib | EXPERIMENTAL | Patients receive olaparib PO BID on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. (Arm Closed as of 8/12/2024) |
| Arm Cobimetinib | EXPERIMENTAL | Patients receive cobimetinib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. (Arm Closed as of 8/12/2024) |
| Arm Onvansertib | EXPERIMENTAL | Patients receive onvansertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. (Arm Closed as of 8/12/2024) |
| Arm Azenosertib | EXPERIMENTAL | Patients receive azenosertib PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. |
| Arm AZD5305 | EXPERIMENTAL | Patients receive AZD5305 PO QD on days 1-10 in the absence of disease progression or unacceptable toxicity. Within 12-24 hours, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. |
| Arm Tremelimumab | EXPERIMENTAL | Patients receive tremelimumab IV over 60 minutes one-time. Within 12-24 hours of cycle completion, patients undergo biopsy or surgery as clinically appropriate per institutional standards for management of patient's disease. |
| Name | Type | Description |
|---|---|---|
| Cobimetinib | DRUG | Given PO |
| Olaparib | DRUG | Given PO |
| Onvansertib | DRUG | Given PO |
| Azenosertib | DRUG | Given PO |
| Saruparib | DRUG | Given PO |
| Tremelimumab | BIOLOGICAL | Given IV |
Inclusion Criteria: * Ability to understand and the willingness to sign a written informed consent document * Age \>= 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Clinically-confirmed diagnosis of resectable, borderline resectable, locally-advanced or metastatic ...